Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Juntendo University
• Treatments: Antipsychotic Agents; Aripiprazole; Haloperidol; Haloperidol decanoate; Methotrimeprazine; Olanzapine; Paliperidone Palmitate; Perphenazine; Quetiapine Fumarate; Risperidone

Criteria

Inclusion Criteria:

• inpatients with a diagnosis of schizophrenia, and

• those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg chlorpromazine eq./day.

Exclusion Criteria:

• mental retardation,

• substance abuse or dependence,

• a history of major head trauma,

• serious medical or neurological disorders, or

• depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months